VYNE Therapeutics Inc. (VYNE)

VYNE Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	26	33	9	55	265	111
Market Cap Growth	330.51%	273.57%	-84.05%	-79.42%	138.35%	16.26%
Enterprise Value	-60	-61	-22	12	241	72
PE Ratio	-	-1.14	-0.37	-0.74	-1.04	-1.17
PS Ratio	62.17	76.70	18.25	58.63	12.64	251.21
PB Ratio	0.32	0.37	0.28	1.12	7.08	6.33
P/FCF Ratio	-1.55	-1.28	-0.30	-0.97	-1.93	-1.50
P/OCF Ratio	-1.55	-1.28	-0.30	-0.97	-1.93	-1.52
EV/Sales Ratio	-100.57	-142.86	-46.69	12.98	11.46	163.41
EV/EBITDA Ratio	1.46	2.13	0.96	-0.18	-0.96	-0.77
EV/EBIT Ratio	1.46	2.13	0.96	-0.18	-0.96	-0.77
EV/FCF Ratio	1.53	2.39	0.76	-0.21	-1.75	-0.97
Debt / Equity Ratio	0.00	0.00	-	0.01	0.93	1.96
Debt / EBITDA Ratio	-0.01	-0.01	-	-0.01	-0.14	-0.37
Debt / FCF Ratio	-0.01	-0.01	-	-0.01	-0.25	-0.46
Quick Ratio	12.41	12.38	3.31	2.74	3.46	2.51
Current Ratio	13.02	12.73	4.10	3.43	4.01	2.61
Asset Turnover	0.01	0.01	0.01	0.01	0.17	0.00
Interest Coverage	-	-	-	-12.15	-57.27	-102.53
Return on Equity (ROE)	-57.90%	-79.10%	-52.90%	-106.50%	-448.20%	-118.10%
Return on Assets (ROA)	-49.80%	-64.20%	-44.80%	-68.00%	-207.40%	-91.00%
Return on Capital (ROIC)	-36.82%	-32.89%	-109.91%	-79.43%	-349.41%	-184.21%
Earnings Yield	-110.58%	-87.49%	-266.62%	-134.33%	-96.35%	-85.53%
FCF Yield	-105.89%	-77.92%	-335.42%	-103.26%	-51.72%	-66.87%
Buyback Yield / Dilution	-1208.17%	-222.44%	-11.44%	-58.75%	-282.06%	-31.22%
Total Shareholder Return	-1208.17%	-222.44%	-11.44%	-58.75%	-282.06%	-31.22%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).